Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07212426) titled 'Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients' on Sept. 30.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Longbio Pharma
Condition:
PNH - Paroxysmal Nocturnal Hemoglobinuria
Intervention:
Drug: Biological/Vaccine: LP-005
Drug: Biological/Vaccine: LP-005
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: November 14, 2024
Target Sample Size: 30
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/...